Antim  llerian hormone levels decrease in female-to-male transsexual @entity1 using XXXX as cross-sex therapy.

@entity1 @entity3610 @entity251 @entity248 @entity9646 @entity2990 @entity2671 @entity342 @entity3800 @entity443
OBJECTIVE: To investigate the effect of hormonal androgenic treatment on antim  llerian hormone ( @entity248 ) serum levels in female-to-male (FtM) transsexual @entity1 . @entity3610 ( @entity3610 ) is associated with elevated @entity248 levels. Some hypothesize that the high @entity248 level is a consequence of @entity342 -induced excessive development of small antral follicles. However, this role of @entity3800 is not yet clear. DESIGN: Observational, prospective, cohort study. SETTING: Tertiary academic medical center. @entity1 (S): Twenty-two FtM transsexual @entity1 , healthy native females receiving cross-sex hormone therapy/androgenic treatment. INTERVENTION(S): Androgenic treatment with @entity251 (T) and an aromatase inhibitor while endogenous hormone secretion was suppressed with the use of a GnRH agonist. MAIN OUTCOME MEASURE(S): @entity9646 concentrations were measured before and after androgenic treatment (administration of T and aromatase inhibitor). Measured hormones: @entity248 , inhibin B, T, @entity2671 , @entity2990 , E2, @entity443 , LH, and FSH. RESULT(S): @entity248 concentrations were significantly lower after androgenic treatment (4.4    4.4   g/L vs. 1.4    2.1   g/L). Androgenic treatment resulted in a strong suppression of @entity248 secretion over a relative short period of 16  weeks. CONCLUSION(S): Our data underscore the likely important role of @entity3800 in the dynamics of folliculogenesis. It challenges the idea that @entity3800 induce high @entity248 levels, which is gaining more interest nowadays as an important particular @entity3610 feature. This strong decline furthermore indicates that @entity248 must be interpreted in the context of other reproductive endocrine conditions. CLINICAL TRIAL REGISTRATION NUMBER: NTR2493.
